| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/08/2006 | US20060122370 Specific binding agents of human angiopoietin-2 |
| 06/08/2006 | US20060122275 Agentfor reducing side effects of diclofenac |
| 06/08/2006 | US20060122270 Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism |
| 06/08/2006 | US20060122268 Such as N1-(1-cyanocyclopropyl)-4-fluoro-N2-((1S)-2,2,2-trifluoro-1-(4' -(methylsulfonyl)-1,1'-biphenyl-4-yl) ethyl)-L-leucinamide; for treating osteoporosis and other bone loss disorders |
| 06/08/2006 | US20060122245 Novel inhibitors of IMPDH enzyme |
| 06/08/2006 | US20060122244 Hypoglycemic agents; antidiabetic agentys; side effect reduction; cardiovascular disorders; anticancer agents |
| 06/08/2006 | US20060122242 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
| 06/08/2006 | US20060122239 Lipid diseases; metabolism diosrders; antiproliferative agents |
| 06/08/2006 | US20060122217 Combination of organic compounds |
| 06/08/2006 | US20060122215 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity |
| 06/08/2006 | US20060122180 Therapeutic treatment |
| 06/08/2006 | US20060122154 1-(2-(Hydroxymethyl)-5-thiolanyl)pyrrolo[2.3d]pyrimidine derivatives or their phosphates: 4-amino-7-(2-C-methyl-4-thio- beta -D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine; hepatitis C virus |
| 06/08/2006 | US20060122151 Composition containing an association of aspirin and an anti-Xa oligosaccharide and use of an anti-Xa oligosaccharide optionally in combination with aspirin |
| 06/08/2006 | US20060122147 Combination preparation of hyaluronic acid and at least oe local anesthetic and the use thereof |
| 06/08/2006 | US20060122105 Method of improing the growth performance of an animal |
| 06/08/2006 | US20060121608 Keratinocytes and culture medium containing ascorbic and linoleic acid, vitamin e, epidermal growth factor; has surface electrical capacitance of given values |
| 06/08/2006 | US20060121529 CpG receptor (CpG-R) and methods relating thereto |
| 06/08/2006 | US20060121480 Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome |
| 06/08/2006 | US20060121465 Sgk and nedd used as diagnostic and therapeutic targets |
| 06/08/2006 | US20060121454 diagnosis and treatment of carcinomas, especially breast cancers |
| 06/08/2006 | US20060121180 Using electrochemical solution containing metal compound and bioactive materials; contacting substrate |
| 06/08/2006 | US20060121118 Antimycotic gel having high active compound release |
| 06/08/2006 | US20060121117 Anti-angiogenic compositions and methods of use |
| 06/08/2006 | US20060121107 Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same |
| 06/08/2006 | US20060121106 Therapeutic system comprising amoxicillin and clavulanic acid |
| 06/08/2006 | US20060121088 delivering to an external portion of the body passageway a therapeutic agent such as an antiangiogenic factor from a thread; treating stenosis or restenosis for example |
| 06/08/2006 | US20060121086 Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound |
| 06/08/2006 | US20060121066 Sucralose formulations to mask unpleasant tastes |
| 06/08/2006 | US20060121041 Gpcs as modifiers of the irrtk p21 pathways and methods of use |
| 06/08/2006 | US20060121035 Methods for treating diabetes |
| 06/08/2006 | US20060121015 Probiotic bifidobacterium strains |
| 06/08/2006 | US20060120992 Rapid dehydration of proteins |
| 06/08/2006 | US20060120977 Controlled delivery system of antifungal and keratolytic agents for local treatment of fungal infections of the nail and surrounding tissues |
| 06/08/2006 | US20060120966 Salmeterol superfine formulation |
| 06/08/2006 | US20060120963 Method of identifying therapeutic compounds for a treatment of hepatic disorders |
| 06/08/2006 | DE20122582U1 Zubereitung für Restenoseprophylaxe Preparation for prophylaxis of restenosis |
| 06/08/2006 | CA2588990A1 Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
| 06/08/2006 | CA2588868A1 Remedy for alzheimer's disease |
| 06/08/2006 | CA2588466A1 Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1 |
| 06/07/2006 | EP1666883A1 Diagnostic and monitoring methods for bone loss |
| 06/07/2006 | EP1666600A1 Methods for enhancing the efficacy of cancer therapy |
| 06/07/2006 | EP1666481A2 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo[2,3]pyrimidine derivatives as protein kinases inhibitors |
| 06/07/2006 | EP1666480A1 Aryl or Heteroaryl Fused Imidazole Compounds as intermediates for Anti-Inflammatory And Analgesic Agents. |
| 06/07/2006 | EP1666092A2 Drug combination comprising a fatty acid and a uridine compound. |
| 06/07/2006 | EP1666071A1 Preparation for the prophylaxis of restenose |
| 06/07/2006 | EP1666070A1 Preparation for the prophylaxis of restenose |
| 06/07/2006 | EP1666067A1 Drug containing chymase inhibitor as the active ingredient |
| 06/07/2006 | EP1666064A1 Remedy for diseases associated with immunoglobulin gene translocation |
| 06/07/2006 | EP1666062A2 Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5c8 |
| 06/07/2006 | EP1666052A1 Uses of agonists and antagonists to modulate activity of TNF-related molecules |
| 06/07/2006 | EP1666047A1 Pharmaceutical compositions comprising nitric oxide-releasing pyrrolidones |
| 06/07/2006 | EP1666045A1 Sphingomyelin containing preparation for the enhancement of tumor therapy and for the treatment of rheumatoid arthritis |
| 06/07/2006 | EP1666042A2 Composition comprising cilobradine and a cardiostimulating agent, e.g. telmisartan |
| 06/07/2006 | EP1666039A1 Use of L-alpha-lysophosphatidylcholine inhibitors to prevent inflammation |
| 06/07/2006 | EP1666033A1 Prevention and treatment of androgen-deprivation induced osteoporosis |
| 06/07/2006 | EP1666029A1 Pressurised metered dose inhalers (MDI) |
| 06/07/2006 | EP1666028A1 Dry powder compositions having improved dispersivity |
| 06/07/2006 | EP1666025A1 DRUG DELIVERY SYSTEM FOR SUB-TENON’S CAPSULE ADMINISTRATION OF FINE GRAINS |
| 06/07/2006 | EP1666024A1 Preparation for rectal administration |
| 06/07/2006 | EP1664852A2 Method for configuring air-core photonic-bandgap fibers free of surface modes |
| 06/07/2006 | EP1664340A1 Sensitivity test to predict efficacy of anti-cancer therapies |
| 06/07/2006 | EP1664275A2 In vivo synthesis of connective tissues |
| 06/07/2006 | EP1664051A2 Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
| 06/07/2006 | EP1663962A2 Compositions and methods for the treatment of disease associated with trp-p8 expression |
| 06/07/2006 | EP1663398A1 Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors |
| 06/07/2006 | EP1663396A2 Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
| 06/07/2006 | EP1663395A1 Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent |
| 06/07/2006 | EP1663313A2 Compositions useful for treating gastrointestinal motility disorders |
| 06/07/2006 | EP1663312A1 Anti cancer combinations comprising a cox-2 inhibitor |
| 06/07/2006 | EP1663311A2 Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| 06/07/2006 | EP1663290A2 Modulators of p-selectin glycoprotein ligand 1 |
| 06/07/2006 | EP1663273A1 Powdery composition for use as a laxative |
| 06/07/2006 | EP1663259A2 Compositions and methods for treatment of cancer |
| 06/07/2006 | EP1663258A2 Pharmaceutical compositions and therapeutic treatment with oligo-beta- (1,3) - glucans |
| 06/07/2006 | EP1663257A1 Method for treating irritable bowel syndrome using laxatives |
| 06/07/2006 | EP1663244A2 Pteridine derivatives for the treatment of septic shock and tnf-alpha-related diseases. |
| 06/07/2006 | EP1663239A2 Potassium channel mediated delivery of agents through the blood-brain barrier |
| 06/07/2006 | EP1663236A1 Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-¬1,3,4-oxadiazol-2-yl| phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a biphosphonate |
| 06/07/2006 | EP1663230A1 Compositions comprising benzo(g)quinoline derivatives and prostaglandin derivatives |
| 06/07/2006 | EP1663224A1 A pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti inflammatory drug |
| 06/07/2006 | EP1663214A1 Cancer treatment with epothilones |
| 06/07/2006 | EP1663208A1 Use of telmisartan for the prevention of vascular headache |
| 06/07/2006 | EP1663203A1 Pharmaceutical compositions for the treatment of organophosphate poisoning |
| 06/07/2006 | EP1663200A2 Combination therapy for glycaemic control |
| 06/07/2006 | EP1663198A1 Pharmaceutical formulations of xanthogenates and inhibitors of viral nucleic acid replication (e.g. aciclovir) |
| 06/07/2006 | EP1663191A1 Novel composition comprising rosiglitazone and another antidiabetic agent |
| 06/07/2006 | EP1663187A2 Antiflatulents in combination with histamine h1-receptor antagonists for treating gastrointestinal disorders |
| 06/07/2006 | EP1663185A1 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss |
| 06/07/2006 | EP1663170A1 Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| 06/07/2006 | EP1663169A1 Antibiotic product, use and formulation thereof |
| 06/07/2006 | EP1663153A1 Combination chemotherapy comprising a liposomal platinum complex |
| 06/07/2006 | EP1663143A2 Solid or semi-solid therapeutic formulations |
| 06/07/2006 | EP1663103A2 Compositions of botanical extracts for cancer therapy |
| 06/07/2006 | EP1663090A1 Calcium zeolite hemostatic agent |
| 06/07/2006 | EP1662908A1 Composition and method for facilitating bone healing |
| 06/07/2006 | EP1662906A1 Compositions for the treatment and prevention of diabetes mellitus |
| 06/07/2006 | EP1662874A2 Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| 06/07/2006 | EP1441591A4 Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response |
| 06/07/2006 | EP1425029A4 Peptidomimetics of biologically active metallopeptides |
| 06/07/2006 | EP1423145B1 Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain |